All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 800+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Merck & Co.’s Keytruda adds another indication, FDA accelerated approval for front-line mesothelioma
Monoclonal antibody, mesothelioma, cancer - Read more

AstraZeneca’s Fasenra lands FDA approval for rare, immune-mediated vasculuar disorder
Monoclonal antibody, eosinophilic granulomatosis with polyangiitis - Read more

Applied Therapeutics’ stock jumps as FDA cancels planned govorestat adcomm
Small molecule, cassic galactosemia - Read more

GE Healthcare’s amyloid imaging software lands FDA clearance
Medical image analysis, PET scan, Alzheimer’s disease - Read more

THE GOOD
Clinical Trials

Bristol Myers Squibb touts positive long-term Zeposia data for MS
Small molecule, multiple sclerosis - Read more

Novartis also showcases long-term Kesimpta data for MS
Monoclonal antibody, multiple sclerosis - Read more

GSK posts positive Ph3 data in Arexvy, Shingrix vaccine co-administration
Vaccine, respiratory syncytial virus, shingles - Read more

Purple Biotech’s positive Ph2 interim data for CM24 in pancreatic cancer
Monoclonal antibody, pancreatic cancer - Read more

Innovent Biologics touts positive IBI363 Ph1 response in colorectal cancer
Fusion protein, colorectal cancer - Read more

THE GOOD
Fundraises

EpicentRx receives US DoD translational reward for RRx-001
Small molecule, radioprotector, chemoprotector, neurodegeneration - Read more

Brenus Pharma $25M Series A
Cancer vaccines, colorectal cancer - Read more

Syntax Bio funding (undisclosed amount)
Stem cell differentiation, CRISPR, platform technology - Read more

PRESENTED BY ENMORE BIO
China's Largest Biotech Event: BIOCHINA 2025

BIOCHINA 2025 will take place from March 13-15, 2025, spanning 50,000 square meters and accommodating 30,000 participants across 3,000 biotech and biopharmaceutical companies with significant involvement from decision-makers - an ideal venue for fostering partnerships for business development and supply chain optimization.

Key topics will include cell and gene therapy, antibody drugs, and vaccines, with exhibits featuring pharmaceutical and biotech upstream suppliers, including CROs and CDMOs.

Register now and receive a 20% discount on your partnering registration! Promo code: TLDR

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Mergers & Acquisitions

Roivant’s dermatology subsidiary Dermavant sold to Organon for $175M upfront + $1B in potential milestones
Dermatology, plaque psoriasis, atopic dermatitis, eczema - Read more

THE GOOD
Partnerships

Novo Nordisk’s $600M biobucks deal with NanoVation Therapeutics, partnering on genetic medicine delivery beyond the liver
Drug delivery, lipid nanoparticle, base-editing therapy - Read more

Ori Biotech deepens partnership with Charles River Laboratories after formers’ recent automated CGT manufacturing platform announcement
Cell & gene therapy manufacturing, automated manufacturing, CDMO - Read more

Axcelead Drug Discovery Partners, Eli Lilly partner on (you guessed it) drug discovery
Small molecule, drug discovery, AI - Read more

THE GOOD
Politics & Policy

US Fed cuts rates; what it means for biotech and VC
Interest rate, biotech funding, venture capital - Read more [Paywall]

Oregon lawmakers mull PBM regulations to support dwindling number of independent pharmacies
Pharmacy benefit managers - Read more

“Greater action is needed” in bolstering US biopharma supply chains with manufacturing tech; US Senators comment
Supply chain, manufacturing tech - Read more [Paywall]

THE GOOD
Research

Ichnos Sciences, Glenmark Innovations trispecific antibody bests Johnson & Johnson’s Tecvayli in shrinking multiple myeloma tumors in mice
Trispecific antibody, multiple myeloma, cancer - Read more

Hoth Therapeutics’ take on anti-nausea agent aprepitant reduced astrocytes, improved cognitive function in Alzheimer’s mouse models
Small molecule, Alzheimer’s disease - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Insilico Medicine posts promising ISM001-055 Ph2a safety data, though doubts swirl regarding efficacy data
Small molecule, idiopathic pulmonary fibrosis - Read more

THE BAD
Patient Access

Theratechnologies’ telegraph early 2025 Engrifta SV supply shortage due to third-party CMO facility shutdown
Peptide, HIV-associated lipodystrophy, contract manufacturing, CMO - Read more

THE BAD
Politics & Policy

Sparks fly between policy experts & lawmakers at Inflation Reduction Act hearing
Inflation reduction act (IRA), drug pricing - Read more

THE UGLY
Opinions

Guardant Health CEO calls cap on Exact Science’s blood-based colon cancer test, makes public wager
Blood test, diagnostics, colon cancer screening - Read more [Paywall]

THE UGLY
Politics & Policy

HRSA threatens Johnson & Johnson with fines, termination from 340B program over “unapproved [340B] rebate proposal“
340 discount pharmacy program, drug rebates - Read more

Novo Nordisk again draws Senator Bernie Sanders’ ire, latter claims former can manufacture Ozempic for <$100/month
GLP-1, obesity, drug pricing - Read more

THE UGLY
Strategic Plans

Everyone decides to jump off the bridge at 23andme, as entire independent board of directors resigns
Genetic testing - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.